7 Microbiome Health Startups Transforming Pediatric and Enterprise Care in 2026
Tiny Health closed a $33 million Series B in late September 2026, bringing its total funding to $46 million, while Evvy raised $40 million two weeks earlier to push vaginal microbiome science into fertility research. Both rounds landed inside a six-week window, and both signal the same thing: microbiome health startups are no longer selling curiosity. They’re selling clinical infrastructure.
So which microbiome health startups actually matter right now? The short answer: Tiny Health and Evvy lead on funding and clinical traction in 2026, backed by companies like Viome, Gemelli Biotech, ENBIOSIS, DayTwo, and Juno Bio filling in pediatric, metabolic, SIBO, and women’s health niches. Each takes a different route into clinics, hospitals, or living rooms, and none of them are immune to the accuracy questions regulators keep raising.
That tension between venture money and measurement science is the real story here. A government lab recently tested seven direct-to-consumer stool kits using identical samples and got wildly different “healthy” and “unhealthy” verdicts back. Keep that in mind as you read the rankings below, because hype and evidence don’t always arrive in the same box.
How These Microbiome Health Startups Were Evaluated
I weighted four things: clinical validation (published studies, not just marketing copy), funding and investor credibility, whether the company serves clinicians or just consumers, and how the company’s own claims hold up against independent accuracy testing. Pediatric gut microbiome testing startups got extra scrutiny because parents are making decisions for kids who can’t consent to wellness experiments. Enterprise microbiome health platforms got judged on whether hospitals and practitioners actually use them, not whether a press release says they might.
1. Tiny Health — Best for Pediatric and Family Microbiome Tracking
Cheryl Sew Hoy started Tiny Health after noticing her two children, born by different delivery methods, developed different allergy and eczema patterns. That origin story shaped the company’s entire pediatric gut microbiome testing startups strategy: catch microbial imbalances early, before they calcify into chronic conditions. The company incorporated the week her second child was born in 2020, and launched its infant gut test two years later.
The pitch has since widened. Tiny Health now runs gut and vaginal microbiome tests across pregnancy, infancy, childhood, and adulthood, using shotgun metagenomic sequencing to detect microbes across more than 120,000 genomes down to the strain level. Tests run about $249 and ship to a customer’s door with a stool swab kit, according to coverage of the September 2026 raise. The company’s first randomized controlled trial found that targeted microbiome interventions cut infants’ odds of developing eczema by 83%, a number worth sitting with given how often parents search for an infant gut microbiome test eczema connection.
What separates Tiny Health from most consumer kits is its enterprise arm, Powered by Tiny. More than 6,000 healthcare practitioners now use the platform, and it has struck integration deals with the Mayo Clinic Executive Health and Longevity Program, the Atria Institute, and Fullscript’s practitioner dispensing network, according to reporting on the deal structure. That Fullscript tie-in matters for anyone searching enterprise microbiome platforms for healthcare providers, since it lets a clinician order a test and a supplement protocol from the same dashboard. B Capital led the Series B, with Nick Whitehead joining the board.
Verdict: strongest pediatric data of any company on this list, and the clearest enterprise distribution strategy. The $5 million Microbiome Research Program it launched alongside the raise should produce more peer-reviewed evidence over the next two years, which this category badly needs.
2. Evvy — Best for Vaginal Microbiome and Women’s Health
Priyanka Jain co-founded Evvy in 2021 with Laine Bruzek and Pita Navarro, betting that the vaginal microbiome held diagnostic signal nobody was systematically collecting. Evvy’s Vaginal Health Test bills itself as the only CLIA-certified, CLEP-approved mNGS test that identifies more than 700 microbes from a single at-home swab, per the company’s own description of the technology. That CLIA-certified mNGS test distinction is the detail clinicians actually care about, since it separates Evvy from wellness kits that never go through lab certification at all.
The company now serves more than 100,000 patients and works with roughly 3,000 practitioners, and it has produced 15 peer-reviewed publications identifying novel bacterial vaginosis subtypes, according to co-founder Priyanka Jain. Catalio Capital Management led the $40 million Series B, and the money is earmarked for a new direction: fertility. Evvy is already running a prospective study inside IVF clinics, tracking links between vaginal microbiome composition and embryo transfer success.
In May 2026 the company shipped EvvyAI, a machine-learning assistant trained on its proprietary dataset that translates raw microbiome data into plain-language guidance and flags when a patient needs a clinician instead of an app. For anyone comparing at-home vaginal microbiome test companies, Evvy is the one with the deepest clinical publication record and the clearest regulatory certification, which puts it ahead of most of its direct competitors like Juno Bio, Ombre, and Daye on paper credibility alone.
Verdict: if vaginal health is the use case, Evvy is the default recommendation among best vaginal microbiome test companies 2026 has to offer, mostly because the certification and publication count are verifiable rather than asserted.
3. Viome — Best for Consumer Longevity and Whole-Body Testing
Viome takes a different technical route than most names on this list, using RNA sequencing instead of DNA-based shotgun metagenomics to measure which genes gut microbes are actively expressing, not just which species are present. The Bellevue, Washington company has raised more than $317 million through a Series D, making it one of the better-capitalized players in direct-to-consumer microbiome testing. Its positioning leans toward longevity and chronic disease prevention rather than a single symptom or life stage.
That broad scope is both the appeal and the limitation. Viome’s health scores and nutrition recommendations cover gut, oral, and blood biomarkers in one subscription, which suits a reader who wants one dashboard instead of five separate kits. It’s a weaker fit for someone specifically researching pediatric microbiome testing for babies with eczema or a narrow clinical question, since the company’s strength is breadth, not depth in any single condition.
Verdict: solid choice for an adult consumer who wants an ongoing wellness subscription, less relevant for parents or clinicians chasing a specific diagnosis.
4. DayTwo — Best for Metabolic and Enterprise Health Platforms
DayTwo grew out of a Weizmann Institute study on personalized glycemic response, and it has counted Mayo Clinic and Johnson & Johnson among its backers and strategic partners over the years. The company’s core product predicts how an individual’s blood sugar responds to specific foods based on their gut microbiome composition, then builds a personalized nutrition plan around that prediction.
This is squarely an enterprise microbiome health platforms play rather than a consumer impulse buy. DayTwo has historically sold through health plans, employer wellness programs, and provider partnerships rather than direct-to-consumer marketing, which puts it in a different lane than Tiny Health or Evvy. It’s a reasonable fit for a benefits manager or clinician asking about enterprise microbiome platforms for healthcare providers focused specifically on metabolic and prediabetic populations rather than gut diversity broadly.
Verdict: narrower clinical focus than the gut-diversity-first startups, but that narrowness is a feature if diabetes risk is the actual problem you’re solving.
5. Gemelli Biotech — Best for SIBO and Clinician-Ordered GI Testing
Gemelli Biotech, founded in 2018, occupies the practitioner-only lane of this list. Its IBS-Smart test measures two antibodies linked to post-infectious irritable bowel syndrome, while its Trio-Smart breath test assesses carbohydrate malabsorption and small intestinal bacterial overgrowth through hydrogen and methane patterns. Both are distributed through Fullscript’s lab partner network, meaning a patient can’t order these directly, a doctor has to.
That gatekeeping is actually the point for microbiome testing for healthcare practitioners as a category. Gemelli’s tests are ordered and interpreted by a clinician alongside patient history and symptoms, not treated as a standalone verdict the way some at-home kits are marketed. The company explicitly notes a negative result doesn’t rule out IBS or other causes of chronic GI symptoms, which is more clinical humility than most DTC microbiome startups volunteer.
Verdict: not pediatric-focused and not a consumer product, but one of the more clinically disciplined options for GI-specific symptoms like bloating and SIBO.
6. ENBIOSIS — Best for AI-Driven Practitioner Nutrition Plans
ENBIOSIS combines at-home sample collection with next-generation sequencing and AI-generated nutrition guidance, and it has published clinical findings in the American Journal of Gastroenterology on patients with GI disorders, according to its Fullscript integration documentation. The service costs around $300 for practitioners and is used primarily by nutritionists, chiropractors, naturopathic doctors, and registered dietitians rather than hospital systems.
What makes ENBIOSIS worth including among microbiome health startups is the practitioner-first distribution model paired with an actual peer-reviewed publication, something several louder competitors still lack. It’s a mid-tier enterprise option: more clinically grounded than a pure consumer app, but smaller in scale than Tiny Health’s 6,000-practitioner network.
Verdict: a reasonable pick for independent functional medicine practices building a microbiome-informed nutrition protocol, though its practitioner base is far smaller than the category leaders.
7. Juno Bio — Best for Lower-Cost Vaginal Microbiome Screening
Juno Bio sits in the same women’s health lane as Evvy but targets a lighter-touch, lower-friction screening experience focused on bacterial vaginosis risk and vaginal flora balance. It’s one of the names that surfaces repeatedly as a direct Evvy competitor in investor and market databases, and it fills a gap for someone who wants a quick vaginal health check without committing to Evvy’s full diagnostic and fertility research ecosystem.
Verdict: a reasonable budget-conscious alternative in the at-home vaginal microbiome test companies space, though it carries less publicly available peer-reviewed backing than Evvy’s 15-publication record.
Comparing the Field
| Startup | Core Focus | Test Method | Pediatric or Enterprise | 2026 Funding Event |
|---|---|---|---|---|
| Tiny Health | Gut and vaginal, lifespan | Shotgun metagenomics | Both | $33M Series B (B Capital) |
| Evvy | Vaginal microbiome, fertility | CLIA-certified mNGS | Both | $40M Series B (Catalio) |
| Viome | Gut, oral, longevity | RNA sequencing | Consumer | Series D (2024, $317M total) |
| DayTwo | Metabolic, glycemic response | Gut microbiome + glucose modeling | Enterprise | Backed by Mayo Clinic, J&J |
| Gemelli Biotech | SIBO, post-infectious IBS | Antibody blood test, breath test | Enterprise (practitioner-only) | N/A |
| ENBIOSIS | GI disorders, AI nutrition plans | Next-gen sequencing + AI | Enterprise (practitioner) | N/A |
| Juno Bio | Vaginal flora screening | At-home swab | Consumer | N/A |
Are At-Home Gut Microbiome Tests Accurate?
Not reliably, according to the most rigorous independent check available. Researchers sent identical, standardized stool samples to seven direct-to-consumer microbiome testing services without telling them it was a test, and got back strikingly different results, including one company that flagged a sample as “unhealthy” when every other lab called it normal.
A peer-reviewed follow-up found that variability between providers was on the same scale as the biological variability between different human donors, which means a kit’s result might say more about which lab you picked than about your actual gut. Methodology explains most of the gap: some companies run 16S rRNA amplicon sequencing, others run full shotgun metagenomics, and read depth and reporting cutoffs vary company to company. A German microbiology researcher summarized the clinical takeaway bluntly: professional endorsement of these consumer kits remains unwarranted without standardized quality criteria across the industry.
This doesn’t mean every microbiome health startups product is worthless. It means a single at-home result should open a conversation with a clinician, not replace one, and it’s exactly why companies building practitioner-facing products (Tiny Health’s clinician network, Gemelli Biotech, ENBIOSIS) carry more clinical weight than kits sold purely direct-to-consumer with no human interpreting the output.
How Much Does a Microbiome Test Cost?
Most consumer-facing gut and vaginal microbiome tests run somewhere between $100 and $300 per kit, depending on sequencing depth and whether a follow-up consultation is included. Tiny Health’s gut and vaginal tests sit around $249. ENBIOSIS charges practitioners roughly $300 per patient test. None of these are routinely covered by insurance, since most fall under general wellness rather than diagnosed medical necessity, so expect to pay out of pocket unless your employer’s wellness benefit or a participating clinic absorbs the cost.
When Microbiome Testing Makes Sense (and When It Doesn’t)
If a pediatrician suspects an eczema or allergy connection worth investigating further, or a fertility clinic wants vaginal microbiome data alongside standard IVF workup, a validated test through a clinician-connected platform earns its cost. The research backing behind Tiny Health’s eczema trial and Evvy’s bacterial vaginosis subtyping work is real, published, and growing.
Skip it, or at least hold your expectations low, if you’re buying a kit hoping for a single definitive verdict on your health with no clinician in the loop. Given the measured inconsistency across providers testing identical samples, a solo at-home result is a conversation starter, not a diagnosis. Anyone symptomatic enough to need an actual treatment plan should pair any kit with a doctor or dietitian who can weigh the result against bloodwork, history, and symptoms, not against a marketing page.
The Bottom Line
The microbiome health startups worth watching in 2026 are the ones pairing consumer convenience with actual clinical infrastructure: Tiny Health’s practitioner network and RCT data, Evvy’s certified lab status and publication record, and smaller players like Gemelli Biotech and ENBIOSIS proving out practitioner-ordered models at smaller scale. If you’re a parent considering a pediatric test, a clinician evaluating a new diagnostic tool, or an investor sizing up the category, start with the companies that publish their methodology and let a human clinician interpret the result. Everyone else is still catching up to the science they’re selling.
Frequently Asked Questions
What is the best microbiome testing company right now
Tiny Health and Evvy lead in 2026 based on funding, clinical publications, and practitioner adoption. Tiny Health covers gut and vaginal testing across the lifespan, while Evvy specializes in certified vaginal microbiome diagnostics with a strong peer-reviewed research record.
Are at-home gut microbiome tests accurate
Independent testing found major inconsistencies when identical samples were sent to seven different providers, with results varying as much as biological differences between unrelated people. Treat any single at-home result as a starting point for a clinician conversation, not a diagnosis.
How much does a microbiome test cost
Most consumer and practitioner-ordered microbiome tests cost between $100 and $300 per kit. Tiny Health’s gut and vaginal tests run about $249, and insurance rarely covers these since they’re classified as wellness products rather than diagnostic medical devices.
What companies offer pediatric or infant gut microbiome testing
Tiny Health is the clearest pediatric specialist, offering infant and child gut tests alongside a randomized controlled trial on eczema prevention. It also serves pregnancy and adult testing, making it one of the few companies covering the full family lifespan.
What is Tiny Health and how does it work
Tiny Health is an Austin-based microbiome intelligence company founded by Cheryl Sew Hoy that uses shotgun metagenomic sequencing to analyze stool and vaginal swab samples. Customers collect a sample at home, mail it in, and receive a report detailing microbial imbalances and personalized recommendations.
How does Evvy’s vaginal microbiome test work
Evvy’s at-home test uses a CLIA-certified metagenomic sequencing method to identify more than 700 microbes from a single vaginal swab. Results feed into EvvyAI for plain-language guidance, with the platform connecting patients to practitioners for conditions needing clinical follow-up.
Which microbiome startups raised funding in 2026
Tiny Health raised a $33 million Series B led by B Capital in September 2026, and Evvy raised a $40 million Series B led by Catalio Capital Management earlier that same month. Both rounds will fund clinical research expansion and new diagnostic categories like fertility.
Do doctors recommend at-home microbiome tests
Most clinicians remain cautious, citing inconsistent results across providers and limited regulatory oversight compared to standard diagnostic tests. Practitioner-ordered options with published validation data, like Gemelli Biotech or Tiny Health’s clinician network, carry more clinical confidence than unsupervised consumer kits.
